Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mar 27, 2023 · Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of...
JEMPERLI - EC Treatment Option for Certain Patients
JEMPERLI is an immunotherapy that may help you fight certain types of advanced or returned endometrial cancer. Discover JEMPERLI, a treatment option. Find information about dosing, side effects, resources, and more.
dMMR and Endometrial Cancer | JEMPERLI (dostarlimab-gxly)
Patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer may benefit from an option like JEMPERLI (dostarlimab-gxly) + CP. See full Indication, Safety, & PI.
FDA Approves Immunotherapy for Endometrial Cancer with …
Apr 22, 2021 · Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on...
FDA D.I.S.C.O. Burst: Jemperli
On February 9, 2023, the FDA approved dostarlimab-gxly (brand name Jemperli) for adult patients with mismatch repair deficient recurrent or advanced endometrial cancer, as determined by an...
Jemperli: Uses, Dosage, Side Effects, Warnings - Drugs.com
Aug 7, 2024 · Jemperli is a cancer immunotherapy used to treat types of endometrial cancer and solid tumors. Jemperli belongs to the class of drugs called programmed death receptor-1 (PD-1)–blocking antibodies. In tumors, a protein (PD-1) on immune cells (T-cells) makes them inactive, preventing them from killing cancer cells.
Jemperli (dostarlimab) plus chemotherapy approved in the US as ... - GSK
Jul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as ...
US FDA expands Jemperli (dostarlimab) plus chemotherapy approval ... - GSK
Aug 1, 2024 · Jemperli is also approved as a single agent for adult patients with dMMR recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
JEMPERLI Given in Combination with Carboplatin and Paclitaxel ...
JEMPERLI is a prescription medicine used to treat adults with a kind of uterine cancer called endometrial cancer. JEMPERLI may be used with the chemotherapy medicines, carboplatin and paclitaxel, and then after that JEMPERLI may be used alone when your cancer has spread outside your uterus (advanced) or your cancer has returned.
FDA Expands Approval for Jemperli in Endometrial Cancer
Aug 2, 2024 · The US Food and Drug Administration (FDA) has approved dostarlimab (Jemperli) in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for all adults with...